News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
